Philogen Ties-up with Big Pharma

Philogen S.p.A., a privately-owned biotechnology company, through its Swiss subsidiary, Philochem AG, has formed two discovery collaborations. The first is with J&J’s biopharma division, Janssen Biotech. The tie-up will look to discover new small molecule-based therapeutics using Philochem’s novel lead-generation technologies. The collaboration was facilitated by Johnson & Johnson Innovation LLC.
 
“We are extremely pleased to establish a new collaboration with Janssen, one of the leaders in the discovery and development of novel pharmaceuticals, with an impressive track record in developing small-molecule based therapeutics,” said Dario Neri, co-founder and president of the scientific advisory board, Philogen.
 
In another deal, the Siena, Italy-based biotech entered into a collaboration and license agreement with Celgene, to discover and develop a new class of immunomodulatory therapeutics.
 
“We are extremely pleased to establish a new collaboration with Celgene, a leader in the discovery and development and commercialization of innovative therapies for patients with high unmet medical needs,” said Duccio Neri, chief executive officer, Philogen.
 
No financial details of either agreement were released.